department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

SIPONIMOD · pharmadog

pharmadog
drugs
SIPONIMOD

drug

patient view →

SIPONIMOD

Marketedupdated 2mo ago

by Aurobindo Pharma USA Inc

Approved

community read0 votes

all catalysts(1)

approval · 1

SIPONIMOD — FDA approval

News(0)

no news has mentioned this drug yet

brand

SIPONIMOD

generic

SIPONIMOD

indication

Relapsing Multiple Sclerosis (RMS)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 13m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

tagApproval2 co-mentions · 1 sources
companyAurobindo Pharma Ltd1 co-mentions · 1 sources
tagSmall Molecule1 co-mentions · 1 sources

Trials studying SIPONIMOD

—A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babiesactive not recruitingn=1,178
phase3Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosisactive not recruitingn=129
phase2Repurposing Siponimod for Alzheimer's Diseaserecruitingn=105
—Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italycompletedn=134
—Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Diseaseno longer available
phase3Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patientscompletedn=185
—Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzentrecruitingn=867
—Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Studyterminatedn=8

more trials →